{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:28:21Z","timestamp":1792787301226,"version":"4.5.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"unspecified","delay-in-days":148,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Exagen Inc"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2026,5,2]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Early and accurate SLE diagnosis is critical to identify and treat inflammatory organ manifestations before irreversible organ damage occurs. Conventional serological tests (anti-double-stranded DNA (anti-dsDNA), anti-Smith) and complement biomarkers (C3\/C4) lack sensitivity in early disease, contributing to diagnostic delays. We conducted systematic analysis of a Multianalyte Assay Panel (MAP) index which integrates cell-bound complement activation products (CB-CAPs) with conventional markers to evaluate its diagnostic performance across diverse US clinical cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Biomarker data from studies conducted between 2011 and 2025 were analysed for 3132 individuals: 1210 who met the 1997 American College of Rheumatology (ACR) classification criteria for SLE, 687 healthy controls and 1235 disease controls. CB-CAPs were measured by semiquantitative flow cytometry; autoantibodies by ELISA; complement C3\/C4 by immunoturbidimetry. Diagnostic ORs (DORs), likelihood ratios (LRs) and sensitivity\/specificity were calculated. Sensitivity between the algorithm and conventional serological and complement tests was compared within the SLE cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Against healthy controls, the MAP index demonstrated the strongest diagnostic accuracy (DOR=105.0) compared with CB-CAPs alone (56.8), anti-dsDNA\/Smith (31.8) and complement C3\/C4 (8.2). Against disease controls, performance of CB-CAPs alone, anti-dsDNA\/Smith and C3\/C4 remained superior (DOR=22.3 vs 20.3, 13.7 and 8.8). The MAP index yielded the highest LR+ (33.7) and lowest LR\u2013 (0.3). Within the SLE cohort, the MAP index showed higher sensitivity than anti-dsDNA (OR=27.5), B lymphocyte-bound C4d (20.8) and erythrocyte-bound C4d (14.6) (all adjusted p&lt;0.001). Integration of the algorithm identified 24.5% more SLE cases than conventional markers (serologies and complement), reducing the proportion of patients with negative serologies and normal complement from 52.0% to 27.5%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MAP index integrating CB-CAPs demonstrated markedly superior diagnostic accuracy and generalisability compared with conventional serological tests alone. Its enhanced sensitivity and specificity address key diagnostic gaps, supporting an earlier more definitive SLE diagnosis with potential for earlier intervention, prevention of organ damage and improved long-term outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/lupus-2026-002002","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:00:26Z","timestamp":1780070426000},"page":"e002002","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical utility of a multianalyte lupus risk score incorporating cell-bound complement activation products: a systematic evaluation"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7652-3826","authenticated-orcid":false,"given":"Vasileios C","family":"Kyttaris","sequence":"first","affiliation":[{"name":"Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1441-5373","authenticated-orcid":false,"given":"Michelle A","family":"Petri","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2502-1372","authenticated-orcid":false,"given":"Daniel J","family":"Wallace","sequence":"additional","affiliation":[{"name":"Kao Autoimmunity Center, Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5524-8642","authenticated-orcid":false,"given":"Jennifer L","family":"Rogers","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard","family":"Busch","sequence":"additional","affiliation":[{"name":"Florida Arthritis Center-American Arthritis and Rheumatology Associates\/Bendcare, Jupiter, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Daniel","sequence":"additional","affiliation":[{"name":"Bay Area Rheumatology, Clearwater, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Concoff","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sepehr","family":"Taghavi","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Touba","family":"Warsi","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Schleif","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Alvarez","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany D","family":"Partain","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4439-1395","authenticated-orcid":false,"given":"Tyler","family":"O\u2019Malley","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mahler","sequence":"additional","affiliation":[{"name":"Exagen, Carlsbad, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"2026052909001969000_13.1.e002002.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-025-02168-0"},{"key":"2026052909001969000_13.1.e002002.2","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000056","article-title":"Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements","volume":"1","author":"Putterman","year":"2014","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1002\/art.41093","article-title":"Complement activation in patients with probable systemic lupus erythematosus and ability to predict progression to American College of Rheumatology-classified systemic lupus erythematosus","volume":"72","author":"Ramsey-Goldman","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2026052909001969000_13.1.e002002.4","first-page":"431","article-title":"Delayed diagnosis adversely affects outcome in systemic lupus erythematosus: cross sectional analysis of the LuLa cohort","volume":"30","author":"Kernder","year":"2021","journal-title":"Lupus (Los Angel)"},{"key":"2026052909001969000_13.1.e002002.5","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2022-000856","article-title":"Lupus spectrum ambiguity has long-term negative implications for patients","volume":"10","author":"Bruce","year":"2023","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.6","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s40258-014-0085-x","article-title":"Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes","volume":"12","author":"Oglesby","year":"2014","journal-title":"Appl Health Econ Health Policy"},{"key":"2026052909001969000_13.1.e002002.7","first-page":"74","article-title":"From first symptoms to diagnosis of systemic lupus erythematosus: mapping the journey of patients in an observational study","volume":"41","author":"Kapsala","year":"2023","journal-title":"Clin Exp Rheumatol"},{"key":"2026052909001969000_13.1.e002002.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keu148"},{"key":"2026052909001969000_13.1.e002002.9","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000157","article-title":"Independent association of glucocorticoids with damage accrual in SLE","volume":"3","author":"Apostolopoulos","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.10","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.40571","article-title":"Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort","volume":"70","author":"Petri","year":"2018","journal-title":"Arthritis Rheumatol"},{"key":"2026052909001969000_13.1.e002002.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080828"},{"key":"2026052909001969000_13.1.e002002.12","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200008)43:8<1801::AID-ANR16>3.0.CO;2-O"},{"key":"2026052909001969000_13.1.e002002.13","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120572"},{"key":"2026052909001969000_13.1.e002002.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205171"},{"key":"2026052909001969000_13.1.e002002.15","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2020-000446","article-title":"Impact of systemic lupus erythematosus disease activity, hydroxychloroquine and NSAID on the risk of subsequent organ system damage and death: analysis in a single US medical centre","volume":"8","author":"Hill","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.16","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/acr.24092","article-title":"Economic evaluation of damage accrual in an international systemic lupus erythematosus inception cohort using a multistate model approach","volume":"72","author":"Barber","year":"2020","journal-title":"Arthritis Care Res"},{"key":"2026052909001969000_13.1.e002002.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2017.04.001"},{"key":"2026052909001969000_13.1.e002002.18","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000345","article-title":"Utility of the AVISE connective tissue disease test in predicting lupus diagnosis and progression","volume":"7","author":"Liang","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.19","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/acr2.11219","article-title":"A multianalyte assay panel with cell-bound complement activation products predicts transition of probable lupus to American College of Rheumatology-classified lupus","volume":"3","author":"Ramsey-Goldman","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"2026052909001969000_13.1.e002002.20","first-page":"1021","article-title":"Complement activation products vs standard ANA testing: treatment outcomes, diagnosis, and economic impact (CAPSTONE) in systemic lupus erythematosus","volume":"28","author":"O\u2019Malley","year":"2022","journal-title":"J Manag Care Spec Pharm"},{"key":"2026052909001969000_13.1.e002002.21","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000349","article-title":"Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE","volume":"6","author":"Wallace","year":"2019","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.22","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000528","article-title":"A multianalyte assay panel with cell-bound complement activation products demonstrates clinical utility in systemic lupus erythematosus","volume":"8","author":"Alexander","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.23","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2019-000377","article-title":"Cell-bound complement activation products associate with lupus severity in SLE","volume":"7","author":"Arriens","year":"2020","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.24","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2018-000263","article-title":"Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE","volume":"5","author":"Merrill","year":"2018","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.25","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2016-000165","article-title":"Reduction in erythrocyte-bound complement activation products and titres of anti-C1q antibodies associate with clinical improvement in systemic lupus erythematosus","volume":"3","author":"Buyon","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.26","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.4103\/jfmpc.jfmpc_1177_24","article-title":"Understanding the impact of delayed diagnosis and misdiagnosis of systemic lupus erythematosus (SLE)","volume":"13","author":"Mitchell","year":"2024","journal-title":"J Family Med Prim Care"},{"key":"2026052909001969000_13.1.e002002.27","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.191187"},{"key":"2026052909001969000_13.1.e002002.28","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2021-000504","article-title":"Frequency, severity and costs of flares increase with disease severity in newly diagnosed systemic lupus erythematosus: a real-world cohort study, United States, 2004-2015","volume":"8","author":"Hammond","year":"2021","journal-title":"Lupus Sci Med"},{"key":"2026052909001969000_13.1.e002002.29","doi-asserted-by":"publisher","DOI":"10.1097\/JOM.0000000000000008"},{"key":"2026052909001969000_13.1.e002002.30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05273-0"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2026-002002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T16:00:29Z","timestamp":1780070429000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2026-002002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,29]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/lupus-2026-002002"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2026-002002","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}